The Microbiome Therapeutics Market has witnessed substantial growth, starting at USD 115.2 million in 2023 and forecasted to surge to USD 1403.14 million by 2031, boasting a remarkable CAGR of 40.16% from 2024 to 2031. This surge is attributed to the increasing understanding of the human microbiome's role in health and disease, driving the development of microbiome-based therapeutics. These therapies offer novel approaches to treat various diseases by targeting the gut microbiota, offering potential solutions for conditions such as inflammatory bowel disease, metabolic disorders, and even certain cancers. Additionally, advancements in technology, particularly in sequencing and bioinformatics, facilitate the identification of microbial signatures associated with disease states, paving the way for personalized microbiome-based interventions. With ongoing research and expanding applications, the microbiome therapeutics market is poised for exponential growth, promising transformative advances in healthcare.